Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial

Abstract Background Ramucirumab plus docetaxel combination therapy (DOC/RAM) for advanced non-small cell lung cancer (NSCLC) achieves favorable outcomes; however, efficacy and safety for patients with brain metastases are still unclear. Methods Eligible patients included those with advanced NSCLC wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2023-06, Vol.28 (6), p.551-e454
Hauptverfasser:	Tanimura, Keiko, Uchino, Junji, Kimura, Hideharu, Hiranuma, Osamu, Chihara, Yusuke, Tanzawa, Shigeru, Takumi, Chieko, Kita, Toshiyuki, Inoue, Koji, Minato, Koichi, Takemoto, Shinnosuke, Nakao, Akira, Yoshimura, Kenichi, Takayama, Koichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Brain Neoplasms - drug therapy Brain Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy, Combination Clinical Trial Results Development and progression Diagnosis Docetaxel Dosage and administration Drug therapy Humans Lung cancer, Non-small cell Lung Neoplasms - pathology Metastasis Ramucirumab Testing Vascular Endothelial Growth Factor A
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!